Loading…
This event has ended. Visit the official site or create your own event on Sched.

View analytic
Tuesday, June 28 • 8:00am - 9:30am
#203: Next Generation Collaborations: Transforming the Industry

Sign up or log in to save this to your schedule and see who's attending!

Limited Capacity seats available

Component Type: Forum
Level: Intermediate
CE: ACPE 1.50 Knowledge UAN: 0286-0000-16-609-L04-P; CME 1.50; IACET 1.50; RN 1.50

“Alone we can do so little; together we can do so much.” Harnessing the power of collaboration truly has the ability to alter the healthcare landscape as we know it today. What is the next generation of collaborations and what will be unique about them? What will change in our organizations in the future, and how will they be different from today? Is collaborative R&D going to become a reality for our industry? What roles will FDA and other stakeholders play? This forum will bring together a diverse panel representing some of the industry’s most influential and powerful organizations for a candid and innovative conversation about what is needed to shake up the current ecosystem and truly transform patient health. Submit your questions in advance for the panelists to annualmeetingprogram@diaglobal.org; subject line: Next Gen Collaborations.

Learning Objectives

Review the role of collaborations to date in better aligning biopharmaceutical R&D with needs and constraints of an evolving health ecosystem; Discuss the impact of coming landscape changes on the industry of tomorrow and needs that new collaborations must address; Describe the stakeholders and innovative elements of the new and transformational collaborations that are emerging.

Chair

Dalvir Gill, PhD

Speaker

Panelist
Margaret A. Anderson, MA

Panelist
Christopher P. Austin, MD

Panelist
Jonathan P. Jarow, PhD

Panelist
C. David Nicholson, PhD

Panelist
Drew Schiller



Chair
avatar for Dalvir Gill

Dalvir Gill

Chief Executive Officer, TransCelerate BioPharma Inc.
Dalvir Gill, PhD, has been CEO of TransCelerate since January 2013. Formerly President of Phase II-IV Drug Development at PharmaNet-i3, Dr. Gill has more than twenty-five years of drug development experience. He holds a BSc from the University of Hertfordshire, a PhD from the Royal Free Hospital School of Medicine in London, and an executive program diploma in the health economics of pharmaceuticals from the Stockholm School of Economics. He is a... Read More →

Speakers
avatar for Margaret Anderson

Margaret Anderson

Executive Director, FasterCures, A Center of the Milken Institute
Margaret Anderson is the executive director of FasterCures, a Washington, DC-based center of the Milken Institute, which is driven by a singular goal – to save lives by speeding up and improving the medical research system. FasterCures focuses on spurring cross-sector collaboration, cultivating a culture of innovation and engaging patients as partners. She is also acting president and CEO of the Melanoma Research Alliance, the largest private... Read More →
avatar for Christopher Austin

Christopher Austin

Director, National Center for Advancing Translational Sciences, National Institutes of Health (NIH)
Christopher P. Austin, M.D., is director of the National Center for Advancing Translational Sciences (NCATS) at the U.S. National Institutes of Health (NIH). Austin leads the Center’s work to improve the translation of observations in the laboratory, clinic and community into interventions that reach and benefit patients—from diagnostics and therapeutics to medical procedures and behavioral changes.
avatar for Jonathan Jarow

Jonathan Jarow

Senior Medical Advisor to the Center Director, CDER, FDA
Dr. Jonathan P. Jarow is currently the senior medical advisor to the Center Director and chair of the medical policy council in CDER at FDA. Jonathan previously served as the director of CDER’s Office of Medical Policy and as deputy director of the Office of Hematology and Oncology Products. Prior to joining the FDA he was Professor of Urology, Pathology, Radiology, and Molecular Biology & Biochemistry at Johns Hopkins University.
avatar for C. David Nicholson

C. David Nicholson

Executive Vice President, Brand R&D, Allergan
Dr. Nicholson joined Actavis as SVP, Global Brands R&D in August 2014. Previously, he served as Chief Technology Officer and EVP, R&D for Bayer CropScience from March 2012 to August 2014; VP of Licensing and Knowledge Management at Merck from 2009 to December 2011; and SVP, responsible for Global Project Management and Drug Safety at Schering-Plough from 2007 to 2009. From 1988 to 2007, Dr. Nicholson held various leadership positions at... Read More →
avatar for Drew Schiller

Drew Schiller

Co-Founder and Chief Technology Officer, Validic
Drew Schiller co-founded Validic and serves as the CTO. At Validic, Drew leads the product and technology strategy, drives key initiatives, and works closely with senior executives at partner organizations to stay ahead of the technology curve. Drew sits on the Consumer Electronics Association (CEA) Health & Fitness Technology Board and contributes to CEA Health & Fitness subcommittees on Interoperability, Privacy and Security, and Standards... Read More →


Tuesday June 28, 2016 8:00am - 9:30am
Ballroom A Pennsylvania Convention Center 1101 Arch Street, Philadelphia, PA 19107 USA